Entourage Health Corp. (ENTG.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.7 Million CAD | -21.95% |
| 2022 | 32.13 Million CAD | 7.04% |
| 2021 | 30.02 Million CAD | 10.16% |
| 2020 | 27.25 Million CAD | 27.47% |
| 2019 | 21.38 Million CAD | 42.82% |
| 2018 | 14.97 Million CAD | 100.33% |
| 2017 | 7.47 Million CAD | 7494.43% |
| 2016 | 98.4 Thousand CAD | 200.2% |
| 2015 | 32.77 Thousand CAD | -74.94% |
| 2014 | 130.82 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.7 Million CAD | -78.58% |
| 2024 Q1 | 5.57 Million CAD | 26.52% |
| 2023 FY | 25.08 Million CAD | -21.95% |
| 2023 Q1 | 7.97 Million CAD | -10.81% |
| 2023 Q4 | 4.4 Million CAD | -25.74% |
| 2023 Q2 | 5.57 Million CAD | -30.08% |
| 2023 Q3 | 5.92 Million CAD | 6.36% |
| 2022 Q2 | 8.68 Million CAD | 26.09% |
| 2022 Q3 | 7.62 Million CAD | -12.13% |
| 2022 FY | 32.13 Million CAD | 7.04% |
| 2022 Q1 | 6.88 Million CAD | -20.9% |
| 2022 Q4 | 8.93 Million CAD | 17.15% |
| 2021 FY | 30.02 Million CAD | 10.16% |
| 2021 Q3 | 4.34 Million CAD | -53.33% |
| 2021 Q4 | 8.7 Million CAD | 100.17% |
| 2021 Q2 | 9.31 Million CAD | 21.83% |
| 2021 Q1 | 7.64 Million CAD | 5.09% |
| 2020 Q3 | 7.45 Million CAD | 37.03% |
| 2020 Q4 | 7.27 Million CAD | -2.38% |
| 2020 Q1 | 7.07 Million CAD | 66.12% |
| 2020 Q2 | 5.44 Million CAD | -23.14% |
| 2020 FY | 27.25 Million CAD | 27.47% |
| 2019 Q3 | 5.26 Million CAD | -13.71% |
| 2019 Q1 | 5.76 Million CAD | -21.87% |
| 2019 Q2 | 6.09 Million CAD | 5.79% |
| 2019 Q4 | 4.26 Million CAD | -18.99% |
| 2019 FY | 21.38 Million CAD | 42.82% |
| 2018 Q2 | 3.39 Million CAD | 116.28% |
| 2018 FY | 14.97 Million CAD | 100.33% |
| 2018 Q4 | 7.37 Million CAD | 177.86% |
| 2018 Q3 | 2.65 Million CAD | -21.88% |
| 2018 Q1 | 1.57 Million CAD | -19.04% |
| 2017 Q2 | 4.24 Million CAD | 704.1% |
| 2017 FY | 7.47 Million CAD | 7494.43% |
| 2017 Q4 | 1.94 Million CAD | 157.06% |
| 2017 Q1 | 528.47 Thousand CAD | 817.8% |
| 2017 Q3 | 754.82 Thousand CAD | -82.24% |
| 2016 Q1 | 6081.00 CAD | -72.98% |
| 2016 Q4 | 57.58 Thousand CAD | 444.66% |
| 2016 Q3 | 10.57 Thousand CAD | -56.26% |
| 2016 Q2 | 24.16 Thousand CAD | 297.43% |
| 2016 FY | 98.4 Thousand CAD | 200.2% |
| 2015 Q3 | 616.00 CAD | -81.9% |
| 2015 FY | 32.77 Thousand CAD | -74.94% |
| 2015 Q2 | 3403.00 CAD | -45.56% |
| 2015 Q1 | 6251.00 CAD | -94.24% |
| 2015 Q4 | 22.5 Thousand CAD | 3554.06% |
| 2014 Q3 | 22.24 Thousand CAD | 0.0% |
| 2014 FY | 130.82 Thousand CAD | 0.0% |
| 2014 Q4 | 108.57 Thousand CAD | 388.09% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 2.96 Million CAD | -25.093% |
| CanadaBis Capital Inc. | 7.1 Million CAD | 47.829% |
| Decibel Cannabis Company Inc. | 40.44 Million CAD | 90.833% |
| Delivra Health Brands Inc. | 7.1 Million CAD | 47.845% |
| Lifeist Wellness Inc. | 17.59 Million CAD | 78.927% |
| Cannara Biotech Inc. | 15.34 Million CAD | 75.834% |
| Medicure Inc. | 13.98 Million CAD | 73.496% |
| PharmaCielo Ltd. | 8.33 Million CAD | 55.501% |
| Rubicon Organics Inc. | 14.22 Million CAD | 73.934% |
| BioSyent Inc. | 17.6 Million CAD | 78.944% |
| Voyageur Pharmaceuticals Ltd. | 1.22 Million CAD | -203.673% |